RxDoctor Payments Data

Stephanie Claus, MD

Family Medicine · Waco, TXNPI 1659673036

Payments from drug & device makers

$773in general payments, 2019–2025

Across 44 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$161
  • Dexcom, Inc.$124
  • Merck$90
  • GSK$84
  • AbbVie$60
  • Novo Nordisk$54
  • plus $203 from 7 others

What the payments were for

  • Food & beverage$773100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC10$161
Dexcom, Inc.8$124
Merck6$90
GSK5$84
AbbVie2$60
Novo Nordisk3$54
Pfizer3$52
AstraZeneca2$40
Cipher Pharmaceuticals US LLC1$38
Biogen1$22
Abbott1$21
Novartis1$17
Boehringer Ingelheim1$13

How this compares

$773 in reported general payments places this provider in the 55th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$2,269
Medicare patients
23
Services billed
174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin81$96,233
OzempicSemaglutide63$64,988
RybelsusSemaglutide33$43,860
TrulicityDulaglutide29$37,406
EliquisApixaban27$23,183
MounjaroTirzepatide16$19,213
RexultiBrexpiprazole11$15,883
Incruse ElliptaUmeclidinium Bromide12$6,369
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,520
Gabapentin70$1,630
Albuterol Sulfate HfaAlbuterol Sulfate66$1,552
Humulin 70-30Insulin Nph Hum/Reg Insulin Hm12$1,401
Aripiprazole15$1,257
Atorvastatin Calcium152$1,149
Fluticasone Propionate70$951

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$54$108,84896 claims
Boehringer IngelheimJardiance$13$96,23381 claims
Lilly USA, LLCTrulicity, Mounjaro, Humulin 70-30$161$58,02057 claims
PfizerEliquis$52$23,18327 claims
GSKIncruse Ellipta$84$6,36912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Waco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →